skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
Material Type:
Article 		Add to My Research

Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease

PloS one, 2021-08, Vol.16 (8), p.e0255335-e0255335 [Peer Reviewed Journal]

COPYRIGHT 2021 Public Library of Science ;2021 Ricke-Hoch et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Ricke-Hoch et al 2021 Ricke-Hoch et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0255335 ;PMID: 34347801

Full text available

Citations Cited by
2
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
Material Type:
Article 		Add to My Research

Fluvastatin mitigates SARS-CoV-2 infection in human lung cells

iScience, 2021-12, Vol.24 (12), p.103469-103469, Article 103469 [Peer Reviewed Journal]

2021 The Author(s) ;2021 The Author(s). ;2021 The Author(s) 2021 ;ISSN: 2589-0042 ;EISSN: 2589-0042 ;DOI: 10.1016/j.isci.2021.103469 ;PMID: 34812415

Full text available

Citations Cited by
3
Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets
Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets
Material Type:
Article 		Add to My Research

Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets

Antimicrobial agents and chemotherapy, 2024-03, Vol.68 (3) [Peer Reviewed Journal]

ISSN: 1098-6596 ;ISSN: 0066-4804 ;EISSN: 1098-6596 ;DOI: 10.1128/aac.01210-23

Digital Resources/Online E-Resources

Citations Cited by
4
Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis
Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis
Material Type:
Article 		Add to My Research

Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis

Antimicrobial agents and chemotherapy, 2020-07, Vol.64 (8) [Peer Reviewed Journal]

Copyright © 2020 American Society for Microbiology. ;Copyright © 2020 American Society for Microbiology. 2020 American Society for Microbiology ;ISSN: 0066-4804 ;EISSN: 1098-6596 ;DOI: 10.1128/AAC.00143-20 ;PMID: 32513799

Full text available

Citations Cited by
5
Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
Material Type:
Article 		Add to My Research

Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages

Antimicrobial agents and chemotherapy, 2022-12, Vol.66 (12), p.e0103222-e0103222 [Peer Reviewed Journal]

Copyright © 2022 Sake et al. ;Attribution ;Copyright © 2022 Sake et al. 2022 Sake et al. ;ISSN: 0066-4804 ;EISSN: 1098-6596 ;DOI: 10.1128/aac.01032-22 ;PMID: 36346232

Full text available

Citations Cited by
6
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
Material Type:
Article 		Add to My Research

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor

Nature communications, 2024-02, Vol.15 (1), p.1173-1173 [Peer Reviewed Journal]

2024. The Author(s). ;The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-024-45241-y ;PMID: 38332002

Full text available

Citations Cited by
7
Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
Material Type:
Article 		Add to My Research

Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease

PloS one, 2021-01, Vol.16 (8), p.e0255335 [Peer Reviewed Journal]

EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0255335

Full text available

Citations Cited by

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait